Certified PEP MEX Expands Its Reach in Mexico With Two New Research Peptide Websites

Nov 7, 2026

Péptidos Verificados brings the full catalog together for online purchase, while Péptido Retatrutida focuses on a molecule as it rounds out its Phase 3 program.

Mexico City, Mexico, November 7, 2026 -- Mexico City, Mexico, 7th November – Certified PEP MEX is a research peptide company that supplies research-use-only (RUO) compounds, and today it announced it is expanding its reach in Mexico with two new websites: Péptidos Verificados at https://peptidosverificados.mx/, where every item in the catalog is available for purchase, and Péptido Retatrutida at https://peptido-retatrutida.mx/, which focuses specifically on retatrutide.

The announcement comes as interest in research peptides continues to grow in the country. Péptidos Verificados brings together 39 compounds in 48 presentations, each with a batch-specific certificate of analysis (COA) and FedEx shipping across Mexico from the official store at https://certified-peptidos.mx/. Péptido Retatrutida offers detailed information on the triple-receptor molecule just as its clinical development approaches a key regulatory stage.

“More and more researchers in Mexico are looking for peptides with documentation they can verify for themselves, and we wanted to give them one clear site with the full catalog and another dedicated to retatrutide as it rounds Phase 3,” said Benson Jamison of Certified PEP. “Every vial carries a QR code that opens the lab report for its batch.”

What Each Site Offers

  • Péptidos Verificados presents the full catalog with a product page, presentation and batch COA for every compound, a dedicated GLP collection, a Spanish-language research library and local pages for sixteen Mexican cities. Every product can be purchased directly on the site, with payment in Mexican pesos.
  • Péptido Retatrutida centers on retatrutide (LY-3437943), a triple agonist of the GLP-1, GIP and glucagon receptors. It includes batch specifications, the COA issued by Vanguard Laboratory, and guides to reading a certificate of analysis and comparing the molecule with tirzepatide and semaglutide.

Prices and availability may change without notice.

Retatrutide: Phase 3 Enters the Home Stretch

On July 23, 2026, Eli Lilly announced positive results from the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, bringing the total to five positive Phase 3 studies for retatrutide. The company plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.

Retatrutide remains an investigational compound and is not approved as a medicine by the FDA or COFEPRIS. The material offered by Certified PEP MEX is a research-grade compound, distinct from the pharmaceutical product used in clinical trials, and is sold strictly for laboratory use. None of the clinical results mentioned constitute claims about Certified PEP MEX products.

Quality and Transparency

Certified PEP MEX peptides are manufactured in the United States in a cGMP-compliant facility and tested by independent laboratories, most often Vanguard Laboratory in Olympia, Washington, which is accredited under ISO/IEC 17025:2017. Every batch has its own COA, and the QR code on each vial opens the report directly on the testing laboratory’s own website.

Research Use Only: Certified PEP MEX products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use, consumption, clinical use, diagnosis, treatment or prevention of disease. No dosing or administration information is provided. Statements in this release have not been evaluated by the U.S. Food and Drug Administration or by COFEPRIS in Mexico.

About Certified PEP MEX

Certified PEP MEX supplies peptides and compounds for qualified laboratory research in Mexico. The company emphasizes U.S. manufacturing, batch-specific independent testing, product labeling with COA information, transparent documentation and customer support in Mexico. Certified PEP MEX products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use or clinical applications.

Contact Info:
Name: Benson Jamison
Email: Send Email
Organization: Certified PEP MEX
Phone: 52 55 8526 4324
Website: https://certified-peptidos.mx/

Release ID: 89208820

In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.

More News
Najib still in jail as lawyers demand immediate house arrest
Najib still in jail as lawyers demand immediate house arrest

Nov 6, 2026

Messrs Shafee & Co says AGC has no legal basis to call for continued detention....

Free water, tuition classes among BN-PN's 113 pledges for Malacca polls
Free water, tuition classes among BN-PN's 113 pledges for Malacca polls

Nov 6, 2026

MALACCA POLLS | Affordable homes and flood mitigation measures included....

Out of Kajang, not yet home: AGC urges pause on Najib's house arrest
Out of Kajang, not yet home: AGC urges pause on Najib's house arrest

Nov 6, 2026

Legal questions over conditional pardon prompt call for further clarification....

Rafizi urges Anwar to drop BN amid growing govt infighting
Rafizi urges Anwar to drop BN amid growing govt infighting

Nov 6, 2026

He warns deteriorating ties could undermine the administration’s ability to govern....

As soon as Najib gets home, I'm gone, says Loke
As soon as Najib gets home, I'm gone, says Loke

Nov 6, 2026

UPDATED 6.27PM | This may happen either tonight or tomorrow....

Bersatu doctor's diagnosis: RM50m can cure many ills, but not kleptocrat condition
Bersatu doctor's diagnosis: RM50m can cure many ills, but not kleptocrat condition

Nov 6, 2026

Afif takes swipe at donation for Najib's prison release....

As Deepavali approaches, ex-MP urges govt to close gaps on Indian representation in civil service
As Deepavali approaches, ex-MP urges govt to close gaps on Indian representation in civil service

Nov 6, 2026

Indian Malaysians make up 6.5pct of the population but only 3.63pct of the civil service....

Anwar: Vote those with direct line to PM, usher change to save M'sia
Anwar: Vote those with direct line to PM, usher change to save M'sia

Nov 6, 2026

MALACCA POLLS | He says this would ensure local communities' concerns and welfare needs are addressed....

Najib pays RM50m fine, leaves prison, but house arrest uncertain
Najib pays RM50m fine, leaves prison, but house arrest uncertain

Nov 6, 2026

Malaysiakini brings you updates live....

Sarawak heads to polls Dec 12
Sarawak heads to polls Dec 12

Nov 6, 2026

Nominations to be held on Nov 28, and early voting on Dec 8, EC says....

Anwar cites Muslim senator’s victory in US as rejection of racism
Anwar cites Muslim senator’s victory in US as rejection of racism

Nov 6, 2026

PM notes Democrats' campaign rejecting racism and religious oppression....

YOURSAY | Character-building need not come at expense of mother tongues
YOURSAY | Character-building need not come at expense of mother tongues

Nov 6, 2026

'National unity and cultural diversity are not mutually exclusive.'...

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

ABOUT US
Akhbar Harian

Akhbar Harian is your minute-to-minute update on Malaysian news keeping you in touch within the local community or in another state.

Contact us: sales[at]akhbarharian.com



SUBSCRIBE
Copyright © 2015 - 2026 Akhbar Harian. All Rights Reserved.